Targeting Nerve Growth Factor, a new option for treatment of osteoarthritis: A Network meta-analysis of comparative efficacy and safety with traditional drugs

CURRENT STATUS: Under Review

Arthritis Research & Therapy  BMC

Ziqin Cao, Pengcheng Dou, Zeling Long, Yihan Li, Jingjing Sun, Jian Zhou, Wanchun Wang

Ziqin Cao
Second Xiangya Hospital

Pengcheng Dou
Second Xiangya Hospital

Zeling Long
Mayor clinic rochester

Yihan Li
University of California Davis Medical Center

Jingjing Sun
Second Xiangya Hospital

Jian Zhou
second xiangya hospital

jian.zhou@csu.edu.cn Corresponding Author

Wanchun Wang
Second Xiangya Hospital

Prescreen

10.21203/rs.3.rs-28823/v1
Subject Areas

**Orthopedics**

Keywords

*Osteoarthritis, nerve growth factor, NSAIDs, Opioids, pain relief, function improvement*
**Abstract**

BACKGROUND: Osteoarthritis (OA) is the most common joint disease and leading cause of pain and disability in the elderly population. Most guidelines recommend the use non-steroidal anti-inflammatory drugs (NSAIDs) and opioids for the non-operative treatment of OA. Monoclonal NGF antibodies are potential for pain relief and function improvement of OA. We conducted this network meta-analysis to comprehensively compare the efficacy and safety of monoclonal NGF antibodies with NSAIDs and opioids for OA.

METHODS: Relevant studies, published up to January 2020, were included from PubMed, CKNI and Web of Science databases. Bayesian network and conventional meta-analyses were conducted. Pain relief, function improvement and risk of adverse effects (AEs) were assessed.

RESULTS: 38 articles, comprising 41 trials (20489 patients with OA) were included. Overall, Anti-NGF was the most efficacious drug for pain relief (SMD compared with placebo 4.25, 95% CIs [2.87 to 5.63], SUCRA=93.7%) and (SMD 4.90, 95% CIs [3.46 to 6.33], SUCRA=98.3%). Although Anti-NGF was associated with higher risk of peripheral sensation abnormality (paresthesia and pruritus), it was not associated with higher withdrawal rates due to AEs and other AEs.

CONCLUSIONS: The results show that monoclonal NGF antibodies significantly relieve pain due to OA and improve function, compared to selective cox-2 inhibitions, NSAIDs, and opioids. The monoclonal NGF antibodies are not associated with severe AEs. However, there is need to conduct more studies to confirm the findings of this study.

**Introduction**

Osteoarthritis (OA) is the most common joint disease and leading cause of pain and disability in the elderly population. Globally, approximately 302 million people suffer from Osteoarthritis every year (1).

OA is a common degenerative disease characterized by cartilage degeneration, osteophyte formation, and synovial inflammation. The disease usually affects the knee, hip, or hand joints. The OA-caused pain symptoms and subsequent physical dysfunction increase the mortality risk (2) as well as the societal economic burden (3). To address the health issue, most guidelines recommend the use non-steroidal anti-inflammatory drugs (NSAIDs) and opioids for the non-operative treatment of OA (1). However, the use of NSAIDs and opioids is limited by the tolerability and safety concerns(4).

In 1950s Levi-Montalcini et al(5) discovered the nerve growth factor (NGF), a new neurotrophin molecule. Subsequent studies have confirmed the crucial effect of NGF in the development of sensory neurons responsible for nociception and temperature sensation. Moreover, evidence shows that the withdrawal or blockage of NGF significantly decreases the sensitivity of peripheral nociceptors and down-regulates expression of neuropeptide (6). This results in adequate pain relief. Subsequently, numerous monoclonal NGF antibodies have been developed. Among the monoclonal NGF antibodies, clinical trials on OA have been conducted using tanezumab, fulranumab and fasinumab, and the high efficacy results were reported (7–15).

Numerous systematic reviews and meta-analyses investigating the efficacy and safety of NSAIDs and/or opioids for treatment of OA pain have been conducted. A recent network meta-analyses compared the pain-reduction efficacy of NSAIDs with opioids (16). The results showed that NSAIDs and opioids are efficacious in pain relief in OA patients. Based on this study, we included 13 types of drugs in our network meta-analysis. Based on these drugs’ activity mechanism, we divided them into 5 groups: Anti-NGF group (tanezumab, fulranumab, fasinumab), potent opioid (oxycodone, hydromorphone, oxymorphone), weak opioid (tramadol), selective COX-2 inhibitor (celecoxib, etoricoxib, rofecoxib), and traditional NSAIDs (ibuprofen, naproxen, diclofenac, paracetamol/acetaminophen). We subsequently assessed the efficacy, including pain reduction and physical function improvement, and the drug’s safety for OA in a bayesian network meta-analysis.
Method

Literature search

We searched the PubMed, CKNI and Web of Science databases, up to January 2020. Our search terms consisted of “Osteoarthritis”, “tanezumab”, “fulranumab”, “fasinumab”, “oxycodone”, “hydromorphone”, “oxymorphone”, “tramadol”, “celecoxib”, “etoricoxib”, “rofecoxib”, “ibuprofen”, “naproxen”, “diclofenac”, and “paracetamol/acetaminophen”. We screened the reference lists of the relevant systematic reviews and meta-analyses to identify eligible articles. All eligible articles were included irrespective of the language of publication.

Inclusion/exclusion Criteria

The inclusion criteria for this network meta-analysis were as follows: 1. randomized clinical trials (RCTs); 2. studies comparing the target drugs with placebo, or each other; 3. studies on patients with OA at any joint; 4. studies reporting the following endpoints: pain reduction, withdrawal due to adverse effects (AEs), and function improvement. The exclusion criteria were as follows: 1. dose-escalation studies of only one drug; 3. target drugs combined with other drugs; 3. studies for postoperative pain; 4. reviews, systematic reviews and meta-analyses, conference abstraction, letters, pharmacokinetical or pharmacodynamical studies, and studies with insufficient data.

Quality Assessment

We strictly used the Cochrane risk of the bias assessment tool to perform the methodological quality assessment of the RCTS. Based on the Cochrane handbook V.5.1.0 (17), we evaluated six indications: sequence generation, allocation concealment, blinding, incomplete outcome data, selection outcome reporting, and other sources of bias. The quality of each indication was evaluated and ranked as low risk of bias, unclear risk of bias, or high risk of bias.

Data Extraction

Author, publication year, total sample size, mean age, gender ratio, affected joint, route of administration, experimental drugs, intervention time, additional follow-up period, and endpoint data were collected and tabulated. To reduce the effect of withdrawal bias, we preferentially collected the data from the intention-to-treat analysis.

Outcome Measures

The primary efficacy endpoint was the pain reduction. The secondary efficacy endpoint was the functional improvement. The change-from-baseline score (mean ± SD) at the last follow-up period was used to evaluate the extent of pain relief. There were restrictions on the types of questionnaire used in pain evaluation. Functional improvement was evaluated using the function subscale of Western Ontario and McMaster Universities Arthritis Index (WOMAC). If the WOMAC function score was not measured or reported, the Lequesne Index or other functional measurement scales was used. For studies involving multiple treatment groups with different doses of the same drug, we selected the most effective dose group based on respective study’s recommendations (18). We calculated the standardized mean difference (SMD) since results from different scales were used in the same network.

Since the patient compliance contributes to the effect of treatment in clinical practice, we selected the withdrawal rates due to AEs as the primary safety endpoint. The most commonly related AEs were labeled as the secondary safety endpoints. We calculated the odds ratio (OR) with 95% confidence intervals (CI) for the safety of target drugs versus placebo or against each other.

Statistical analysis

Direct pairwise meta-analyses was performed to compare the efficacy of the target drugs with placebo using
Review Manager Software (version 5.3). The heterogeneity across studies was tested by the Q and I2 statistic, in which P < 0.05 or I2 > 50% was considered significantly heterogeneous. After that, a random-effects model was used to test the significant heterogeneity across studies, otherwise, a fixed-effects model was preferred. The Bayesian network meta-analyses were conducted using Stata/MP (version 14.0, Stata Corp, College Station, Texas, USA) and GeMTC (version 0.14.3). This method increases the number of studies within each comparison and narrows the CIs’ width, resulting in stable results (19–22). In the Bayesian network meta-analysis, non-informative uniform and normal prior distributions was used. Subsequently, four different sets of starting values were set to fit the model to yield 40000 iterations (10000 per chain) and obtain the posterior distributions of model parameters (23, 24). The thinning interval was set at 10 and the burn-ins at 1000, for each chain. Convergence of iterations was assessed using the Gelman-Rubin-Brooks statistic (25). Global inconsistency tests and local inconsistency tests (Loop-inconsistency tests and Node-split tests) were used to reconfirm the consistency of the network meta-analysis. Three subgroup analyses were conducted. The first one was used to verify the impact of the results of the network analyses whether the included trials were commercially funded or not. The second one was to find the optimum one for both pain relief and physical function improvement from different selective COX-2 inhibitor and traditional NSAIDs (celecoxib, etoricoxib, rofecoxib, Iburofen, naproxen, diclofenac, paracetamol/acetaminophen) versus placebo.

All estimate outcomes (SMDs or ORs) with 95% CIs were generated from the posterior distribution medians. Significant differences were considered at the 95% CI excluding 0 for the SMD or 1 for OR. Surface under the cumulative ranking (SUCRA) was used to rank the efficacy and safety of different drugs. To select the most effective drug simultaneously for the two or more endpoints, cluster-ranking plots constructed.

### Results

#### Study selection

This network meta-analysis was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (26).

A total of 38 articles, including 41 trials (7–15, 27–55), were included. The selection criteria is shown in Supplementary appendix Fig. 1. Five treatment arms (Anti-NGF, potent opioid, weak opioid, selective COX-2 inhibitor, and NSAIDs ) and eight treatment arms (celecoxib, etoricoxib, rofecoxib, Iburofen, naproxen, diclofenac, paracetamol/acetaminophen and placebo) were included into the network of the main and subgroup analyses, respectively (Fig. 1).

#### Study Characteristics

A total of 20489 patients were included in to the study. Among the 41 eligible articles, only one study with 385 patients was on hand-joint OA. Across the trials, the mean age of the patients was 61.25 years (ranged from 57.41 to 70.00 years), the proportion of male patients was 32.26% (ranged from 19.57–54.03%), and the median follow-up was 84 days (IQR 42–84 days). The number of assessed patients for each treatment were 5408 (NSAIDs), 4131(selective COX-2 inhibitor), 3108 (anti-NGF), 1405 (weak opioids), and 1274 (potent opioids).

The baseline characteristics of the included studies are shown in Supplementary appendix Table 1. The methodological quality and risk of bias were evaluated for all included trials (Supplementary appendix Table 2). Based on this results, the main contributing factors to risks of bias were performance bias, selection bias, and attrition bias.
| Comparison                  | No. of trials | No. of pts | Target joint | Mean age (range) | Male % | Mean FU periods (days, range) | SMD (95%CI) for pain relief |
|----------------------------|---------------|------------|--------------|------------------|--------|-----------------------------|-----------------------------|
| Anti-NGF vs placebo        | 9             | 2348       | Hip and Knee | 59.98 (57.41–62.32) | 0.3667 | 102.67 (56–224)             | 4.182(3.778,4.586)        |
| Potent opioids vs placebo  | 5             | 1528       | Hip and Knee | 61.10 (57.41–65.52) | 0.3662 | 81.2 (14–112)               | 0.807 (-1.527,3.140)      |
| Weak opioids vs placebo    | 2             | 805        | Hip and Knee | 59.09 (58.10-60.02) | 0.3723 | 84                          | 3.451(1.722,5.180)        |
| Selective cox-2 inhibition vs placebo | 9             | 2917       | Hip and Knee | 62.81 (60.02–64.77) | 0.2863 | 60.67 (42–84)               | 4.775(2.836,6.714)        |
| NSAIDs vs placebo          | 20            | 6833       | Hand, Hip and Knee | 62.55 (58.66-70.00) | 0.299 | 55.65 (21-84)               | 2.573(1.789,3.357)        |
Table 2

Detailed results of network meta-analysis for pain (Red) and function (Blue) (Data are standardised mean difference, from the top left to the bottom right, higher comparator vs lower comparator, and their related 95% CI)

|            | Anti-NGF   | Selective cox-2 inhibition | Weak opioids | NSAIDS     | Potent opioids | Placebo    |
|------------|------------|----------------------------|--------------|------------|---------------|------------|
|            | 2.34 (0.38, 4.29) | 0.15 (-3.09, 3.38)            | 0.39 (-2.83, 3.60) | 0.83 (-1.42, 3.09) | 1.20 (-0.81, 3.21) |           |
|            | 2.48 (-0.93, 5.89) | 0.53 (-0.77, 1.84)            | 1.22 (-2.47, 4.91) | 2.03 (0.97, 3.09) |               |           |
|            | 2.87 (1.16, 4.57) | 1.36 (-1.07, 3.80)            | 2.42 (-0.68, 5.52) |           |               |           |
|            | 3.70 (1.43, 5.96) | 4.90 (3.46, 6.33)             |              |           |               |           |
|            | 4.90 (3.46, 6.33) | 2.56 (1.17, 3.95)             |              |           |               |           |

Primary Efficacy Endpoint

Direct pair-wise meta-analysis

The efficacies of all the drugs were superior to placebo, for pain relief except for potent opioid with no significant difference (0.807, 95% CIs [-1.527 to 3.140]). Notably, Anti-NGF had the highest significant, for pain relief (SMD 4.817, 95% CIs [3.077 to 6.557]). The details of the pairwise meta-analysis for all drugs compared with placebo are shown in Table 1.

Network Meta-analysis

A total of 38 trials were analyzed. No significant inconsistency was reported in loop-inconsistency estimates, node-split tests, and global inconsistency tests. The consistency model was statistically significant than the inconsistency model.

Anti-NGF was the most efficacious drug (SMD compared with placebo 4.25, 95% CIs [2.87 to 5.63]) for OA pain relief. The potent opioid drug had the lowest efficacy (SMD 0.90, 95% CIs [-1.04 to 2.84]) (Figure 2 and Table 2). Based on the SUCRA value, Anti-NGF was the most efficacious drug in pain relief (SUCRA=93.7%), followed by selective COX-2 inhibitor (SUCRA=69.0%), and lastly opioids (SUCRA=67.3%). The details of the SUCRA rank are shown in Supplementary appendix Table 3.

The subgroup analysis results showed a consistent trend, even after eliminating did all non-funded trials (10 trials). Anti-NGF was still the most efficacious drug for pain relief (SURCA 92.4%, SMD=4.30, 95% CIs [2.85 to 5.74]). The detailed results are shown in the Supplementary appendix Table 4.

Secondary Efficacy Endpoint

Direct pair-wise meta-analysis
Except for the potent opioids (SMD 1.058, 95% CIs [-1.012 to 3.127]), there was a significant difference in efficacy both in the Anti-NGF and selective COX-2 inhibitor drugs compared to placebo. Anti-NGF had the highest efficacy for physical function improvement (SMD 5.108, 95% CIs [3.165 to 7.051]). The details of the pairwise meta-analysis for all drugs compared with placebo are presented in Table 1.

**Network meta-analysis**

A total of 38 trials were analyzed. No significant inconsistency was reported. The consistency model was statistically significant compared to the inconsistency model. Similarly, Anti-NGF drug had the highest efficacy for physical function improvement (SMD 4.90, 95% CIs [3.46 to 6.33]) (Figure 2). The lowest efficacy was reported in potent opioid drug (SMD 1.20, 95% CIs [-0.81 to 3.21]) (Figure 2 and Table 2). For physical function improvement, the most efficacious drug based on SURCA, was Anti-NGF (SURCA=98.3%), followed by selective COX-2 inhibitor (SURCA=63.5%) and opioids (SURCA=56.7%) (Supplementary appendix Table 3). There was no significant difference in the subgroup analysis of the trials with commercial funding. For physical function, Anti-NGF had the highest efficacy (SURCA 97.6%, SMD 4.96, 95% CIs [3.42 to 6.50]) (Supplementary appendix Table 4).

**Primary Safety Endpoint**

**Direct pair-wise meta-analysis**

Except for selective COX-2 inhibitor (OR 0.742, 95% CIs [0.436 to 1.261]), there were significant differences in both Anti-NGF and Opioids in the withdrawal rate due to AEs (Supplementary appendix Table 5).

**Network meta-analysis**

In the withdrawal due to AEs network, a total of 36 trials were assessed. Loop-inconsistency estimates, node-split tests, and global inconsistency tests were performed, and no inconsistency was reported.

Significantly higher withdrawal rates due to AEs were reported in potent opioids (OR 8.63, 95% CIs [5.42, 13.77]), weak opioids (OR 3.27, 95% CIs [1.89, 5.66]), and NSAIDs (OR 1.36, 95% CIs [1.04, 1.77]) compared to placebo. Selective COX-2 inhibitor (SURCA = 93.4%) was reported as the most safe drug, followed by anti-NGF (SURCA=53.5%), and NSAIDs (SURCA=50.5%) (Supplementary appendix Table 3). The subgroup analysis showed that there was no significant change in results, after adjusting the network based on whether trials were funded (Supplementary appendix Table 4). There was no statistical difference reported after excluding the trials with short follow-up. The cluster-rank plots of primary efficacy and primary safety indicated the safest drug was selective Cox-2 inhibition (Supplementary appendix Figure 2).

**Network meta-analysis**

In the headache network, the most efficacious drug was NSAIDs (OR 0.82, SURCA 90.3%, 95% CIs [0.63 to 1.06]). However, no significant differences were reported between the remaining treatments and placebo.

NSAIDs (OR 1.48, 95% CIs [1.04 to 2.13]), weak opioids (OR 3.90, 95% CIs [1.82 to 8.36]) and potent opioids (OR 6.33, 95% CIs [3.37 to 11.90]) had significantly higher risks for nausea AEs. The incidence rates of peripheral sensation abnormality AEs was significantly higher in anti-NGF (OR 3.64, 95% CIs [1.87 to 7.10]), weak opioids (OR 5.25, 95% CIs [1.95 to 14.15]) and potent opioids (OR 5.39, 95% CIs [2.41 to 12.06]) (Table 3). No subgroup analysis was conducted for secondary safety endpoints because of the insufficient number of trials included.

Table 3. Adverse effects of different treatment compared with placebo according to direct pair-wise meta analysis and network meta-analysis (AE, adverse effect; PSA, peripheral sensation abnormality; SURCA, surface under the cumulative ranking.)
| Treatment               | OR(95%CI)                  | Direct | Network meta-analysis | SURCA(%) |
|-------------------------|----------------------------|--------|-----------------------|----------|
| **Withdrawl due to AEs**|                            |        |                       |          |
| Placebo                 | Reference                  | Reference |                  | 82.3     |
| Anti-NGF                | 1.677(1.045,2.692)         | 1.36   | 0.82,2.27             | 53.5     |
| Potent Opioids          | 5.265(3.705,7.482)         | 8.63   | 5.42,13.77            | 0.1      |
| Weak Opioids            | 2.798(1.348,5.807)         | 3.27   | 1.89,5.66             | 21.0     |
| Selective cox-2 inhibition | 0.742(0.436,1.261)     | 0.89   | 0.64,1.24             | 93.5     |
| NSAIDs                  | 1.272(1.028,1.573)         | 1.36   | 1.04,1.77             | 50.5     |
| **Headache AEs**        |                            |        |                       |          |
| Placebo                 | Reference                  | Reference |                  | 53.3     |
| Anti-NGF                | 0.970(0.634,1.483)         | 1.03   | 0.68,1.57             | 49.3     |
| Potent Opioids          | 1.283(0.897,1.837)         | 1.19   | 0.78,1.82             | 29.2     |
| **Continued**           |                            |        |                       |          |
| Weak Opioids            | 1.305(0.709,2.399)         | 1.41   | 0.88,2.25             | 12.4     |
| Selective cox-2 inhibition | 0.748(0.528,1.060)     | 0.93   | 0.68,1.27             | 65.4     |
| NSAIDs                  | 0.928(0.733,1.175)         | 0.82   | 0.63,1.06             | 90.3     |
| **Nause AEs**           |                            |        |                       |          |
| Placebo                 | Reference                  | Reference |                  | 74.2     |
| Anti-NGF                | 0.962(0.504,1.837)         | 0.79   | 0.41,1.53             | 88.7     |
| Potent Opioids          | 4.519(3.212,6.358)         | 6.33   | 3.37,11.90            | 3.3      |
| Weak Opioids            | 3.131(2.054,4.775)         | 3.90   | 1.82,8.36             | 17.0     |
| Selective cox-2 inhibition | 0.825(0.398,1.708)     | 0.99   | 0.64,1.52             | 75.8     |
| NSAIDs                  | 1.432(0.947,2.165)         | 1.48   | 1.04,2.13             | 41.1     |
| **Psa AEs**             |                            |        |                       |          |
| Placebo                 | Reference                  | Reference |                  | 82.7     |
| Anti-NGF                | 4.184(2.010,8.707)         | 3.64   | 1.87,7.10             | 30.7     |
| Potent Opioids          | 5.331(2.731,10.407)        | 5.39   | 2.41,12.06            | 14.2     |
| Weak Opioids            | 8.371(2.935,23.870)        | 5.25   | 1.95,14.15            | 15.4     |
| Selective cox-2 inhibition | 0.777(0.021,28.890)    | 0.96   | 0.39,2.39             | 82.6     |
| NSAIDs                  | 0.966(0.633,1.473)         | 1.13   | 0.67,1.90             | 74.4     |

**Subgroup analysis of efficacy between NSAIDs and selective COX-2 inhibitor**

A total of 24 trials, assessing the efficacy of NSAIDs or selective COX-2 inhibitor, were included. Etoricoxib was the most efficacious drug for both pain relief (SMD 3.20, 95% CIs [1.17 to 5.24]) and function improvement (SMD 3.41, 95% CIs [1.88 to 4.93]). All drugs had significantly higher efficacies compared to placebo for both pain relief and function improvement (Figure 2 and Supplementary appendix Table 6). However, no significant difference was reported between different drugs. Based on the cluster-rank plot, etoricoxib was the efficacious drug (Supplementary appendix Figure 2).

**Secondary Safety Endpoint**

After selection of the studies, the incidence rates of the three most common AEs, including nausea, headache, and peripheral sensation abnormality (paresthesia and pruritus) were selected for secondary safety endpoints. A total of 33 trials were assessed.

**Direct Pair-wise Meta-analysis**
There were no significant difference in headache AEs among the three drugs from the pair-wise meta-analyses. However, potent opioids and weak opioids had significantly higher risks for nausea or peripheral sensation abnormality AEs. Besides, Anti-NGF had significantly higher risk for peripheral sensation abnormality AEs (Table 3).

Discussion

This is the first network meta-analysis study comparing the efficacy and safety of the monoclonal NGF antibodies, NSAIDs, opioids, and selective cox-2 inhibitors directly or indirectly, simultaneously. The Bayesian Network used in this study increases the number of studies within each comparison. This network increases the robustness and power of the results. Our results showed that, (1) monoclonal NGF antibody drugs have the highest efficacy for treatment of OA, and had no significant difference compared to selective cox-2 inhibitors, NSAIDs, and opioids; (2) regarding safety and efficacy, the potent opioid drugs are safe and efficacious for the treatment of OA; (3) monoclonal NGF antibodies have the highest efficacy for both pain relief and function improvement, while selective cox-2 inhibitions are the safest and the most suitable choice for long-term treatment of OA (because of the lowest risk of withdrawal due to AEs); (4) etoricoxib seemly was the most efficacious for both pain relief and function improvement based on cluster-rank and SURCA. However, no significant difference was reported between etoricoxib and other selective cox-2 and NSAIDs.

A previous network meta-analysis (16) reported that NSAIDs, weak opioids, and potent opioids have equivalent efficacies for pain relief in OA patients. However, no direct comparison between the potent opioids and other drugs was conducted in this study. Moreover, only one indirect comparison of the drugs with the placebo was performed in the study (16). Therefore, the findings about opioids in this study lack robustness. Based on this study, we included more eligible studies, directly or indirectly comparing potent opioids with other drugs into this study. Additionally, we analyzed for function improvement and the safety of the drugs, which are equally important as pain relief in OA treatment.

The novelty of this study; monoclonal NGF antibodies have the highest efficacy for pain relief and function improvement, exceeding that of selective cox-2 inhibitors, NSAIDs, and weak opioid (tramadol), which are recommended in the American College of Rheumatology/Arthritis Foundation Guideline of 2019 (1). However, monoclonal NGF antibodies have a higher risk of peripheral sensation abnormality (including paresthesia and pruritus). Additionally, its overall withdrawal rate due to AEs is not significantly different compared to placebo. Our findings are consistent with the results of previous systematic reviews (56, 57). Based on our results, monoclonal NGF antibodies constitute the most effective treatment option for OA. The monoclonal NGF antibodies should be the first choice for patients with pain symptoms and/or disability due to OA. However, for patients with paresthesia and pruritus, selective cox-2 inhibitors and NSAIDs are best treatment options. The choice of selective cox-2 inhibitors and NSAIDs can be made based on the mean rank order presented in Supplementary appendix Table 5.

However, this study had several limitations. Firstly, we included only RCTs in our study, based on the unmanageable confounding factors. We omitted observational studies or any other non-RCTs from this network meta-analysis despite of their significance in examining drug effectiveness and safety of treatment for OA. This may have contributed to the small number of studies included. Secondly, only high-quality studies were included. This was done to control the quality of this analysis and minimize the impacts of small study effects. However, the omitted small increase generalizability and robustness of results. The publication bias may be a significant problem. It is difficult to control since it was on a small number of studies. Thirdly, the length of follow-up is closely related to safety profiles as it is not possible to measure long-term outcomes for drug safety, especially for those with short (1–6 weeks) follow-up period. Even though the median follow-up of this network-analysis was 84 days (IQR 42–84 days), it is still not enough to to assess long-term outcomes for safety, particularly for these AEs with mild and chronic symptoms, such as hypertension and sensation abnormality events. More high-quality trials, with long-term follow-up, are needed.
Conclusion

A total of 38 studies comprising of 20489 patients were included in this network meta-analysis. The results show that monoclonal NGF antibodies significantly relieve pain due to OA and improve function, compared to selectivecox-2 inhibitions, NSAIDs, and opioids. The monoclonal NGF antibodies are not associated with severe AEs. However, there is need to conduct more studies to confirm the findings of this study.

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Competing interests: The authors declare that they do not have any competing interests.

Funding: This work was supported by the Mittal Innovation Project of Central South University (Grant No. GCX20190879Y) and the Fundamental Research Funds for the Central Universities of Central South University (Grant No. 2018zzts930). The study funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author contributions:

Jian Zhou and Wanchun Wang conceived the study, participated in its design and coordination, and critically revised the manuscript. Ziqin Cao, Zeling Long and Yihan Li had full access to all of the data collection, analysis, interpretation and drafted the manuscript. Jian Zhou, Jingjing Sun, Pengcheng Dou and Wanchun Wang were study investigators and contributed to the process of data collection. All authors read and approved the final manuscript.

References

1. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. ARTHRITIS RHEUMATOL. [Journal Article]. 2020 2020-02-01;72(2):220–33.
2. Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. [Journal Article; Research Support, Non-U.S. Gov't]. 2011 2011-03-08;342:d1165.
3. Institute of Medicine US Committee on Advancing Pain Research CA, Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington (DC): National Academies Press (US); 2011.
4. Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthritis. LANCET. [Journal Article; Research Support, Non-U.S. Gov't; Review]. 2015 2015-07-25;386(9991):376–87.
5. Levi-Montalcini R. The nerve growth factor 35 years later. SCIENCE. [Journal Article; Review]. 1987 1987-09-04;237(4819):1154–62.
6. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. TRENDS NEUROSCI. [Journal Article; Review]. 1996 1996-11-01;19(11):514–20.
7. Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. PAIN. [Clinical Trial,
Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2013 2013-09-01;154(9):1603–12.
8. Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, et al. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. JAMA. [Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2019 2019-07-02;322(1):37–48.
9. Mayorga AJ, Wang S, Kelly KM, Thipphawong J. Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. INT J CLIN PRACT. [Journal Article; Randomized Controlled Trial]. 2016 2016-06-01;70(6):493–505.
10. Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J RHEUMATOL. 2014;41(11):2249–59. [Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2014-11-01.
11. Tiseo PJ, Kivitz AJ, Ervin JE, Ren H, Mellis SJ. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. PAIN. [Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2014 2014-07-01;155(7):1245–52.
12. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage. [Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial]. 2011 2011-12-01;19(12):1405–12.
13. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. [Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't]. 2010 2010-10-14;363(16):1521–31.
14. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. [Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2013 2013-07-01;65(7):1795–803.
15. Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, et al. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase Ib/II Double-Blind, Placebo-Controlled, Randomized Clinical Trial. ARTHRITIS RHEUMATOL. [Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2019 2019-11-01;71(11):1824–34.
16. Smith SR, Deshpande BR, Collins JE, Katz JN, Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. [Journal Article; Review]. 2016 2016-06-01;24(6):962–72.
17. Higgins JPTGSE. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from .
18. Higgins JPTDJAD. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from .
19. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. [Journal Article; Review]. 2005 2005-10-15;331(7521):897–900.
20. Caldwell DM, Welton NJ, Ades AE. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J CLIN EPIDEMIOL. [Journal Article; Research Support, Non-U.S. Gov't]. 2010 2010-08-01;63(8):875–82.
21. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. STAT MED. [Comparative Study; Journal Article]. 2004 2004-10-30;23(20):3105–24.
22. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J CLIN EPIDEMIOL. [Comparative Study; Journal Article; Research Support, Non-U.S. Gov't]. 1997 1997-06-01;50(6):683–91.
23. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, et al. Bayesian methods for evidence
synthesis in cost-effectiveness analysis. PHARMACOECONOMICS. [Journal Article; Review]. 2006 2006-01-20;24(1):1-19.

24. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. PHARMACOECONOMICS. [Journal Article; Research Support, Non-U.S. Gov't; Review]. 2008 2008-01-20;26(9):753–67.

25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. [Guideline; Journal Article; Research Support, Non-U.S. Gov't]. 2009 2009-07-21;339:b2535.

26. Kivitz A, Ma C, Ahdieh H, Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. CLIN THER. [Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2006 2006-03-01;28(3):352–64.

27. Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart D, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. CURR MED RES OPIN. [Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2003 2003-01-20;19(8):725–36.

28. Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. [Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2007 2007-12-01;15(12):1348–56.

29. Vojtassak J, Vojtassak J, Jacobs A, Rynn L, Waechter S, Richarz U. A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee. Pain Res Treat. [Journal Article]. 2011 2011-01-20;2011:239501.

30. Prior MJ, Harrison DD, Frustaci ME. A randomized, double-blind, placebo-controlled 12 week trial of acetaminophen extended release for the treatment of signs and symptoms of osteoarthritis. CURR MED RES OPIN. [Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2014 2014-11-01;30(11):2377–87.

31. Emery P, Koncz T, Pan S, Lowry S. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. CLIN THER. [Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2008 2008-01-01;30(1):70–83.

32. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. SCAND J RHEUMATOL. [Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2001 2001-01-20;30(1):11-8.

33. Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J RHEUMATOL. [Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2009 2009-09-01;36(9):1991–9.

34. Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. [Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial]. 2004 2004-08-17;171(4):333–8.

35. Gibofsky A, Hochberg MC, Jaros MJ, Young CL. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study. CURR MED RES OPIN. [Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2014 2014-09-01;30(9):1883–93.

36. Essex MN, O'Connell MA, Behar R, Bao W. Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study. INT J RHEUM DIS. [Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2016 2016-03-01;19(3):262–70.

37. Reed K, Collaku A, Moreira S. Efficacy and safety of twice daily sustained-release paracetamol formulation for osteoarthritis pain of the knee or hip: a randomized, double-blind, placebo-controlled,
12. Forster ID, Corrigan C. Efficacy and tolerability of tramadol hydrochloride extended-release once-daily in osteoarthritis of the knee: a 12-week, double-blind, placebo-controlled trial. Curr Med Res Opin. 2008;24(12):2399–408.

13. DeLemos BP, Xiang J, Benson C, Gana TJ, Pascual ML, Rosanna R, et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther. 2006;13(2):77–86.

14. Gana TJ, Pascual ML, Fleming RR, Schein JR, Janagap CC, Xiang J, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin. 2006;22(7):1391–401.

15. Svensson O, Malmenas M, Fajutrao L, Roos EM, Lohmander LS. Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36. Ann Rheum Dis. 2006;65(6):781–4.

16. Rautk R, Rapport R, Thipphawong J. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS(R) hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis. Pain Pract. 2013;13(1):18–29.

17. Miceli-Richard C, Le Bars M, Schmидely N, Dougdados M. Paracetamol in osteoarthritis of the knee. Ann Rheum Dis. 2004;63(8):923–30.

18. Varadi G, Zhu Z, Blattler T, Hosle M, Loher A, Pokorny R, et al. Randomized clinical trial evaluating transdermal Ibuprofen for moderate to severe knee osteoarthritis. Pain Physician. 2013;16(6):E749-62.

19. Altman RD, Zinsenheim JR, Temple AR, Schweinle JE. Three-month efficacy and safety of acetaminophen extended-release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage. 2007;15(4):454–61.

20. Schnitzer TJ, Tesser JR, Cooper KM, Altman RD. A 4-week randomized study of acetaminophen extended-
release vs rofecoxib in knee osteoarthritis. Osteoarthritis Cartilage. [Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2009 2009-01-01;17(1):1–7.

52. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med. 2000;160(12):1781–7. [Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. . 2000-06-26.

53. Ehrich EW, Schnitzer TJ, Mcllwain H, Levy R, Wolfe F, Weisman M, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J RHEUMATOL. [Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 1999 1999-11-01;26(11):2438–47.

54. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum. [Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. 2000 2000-05-01;43(5):978–87.

55. Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. [Journal Article; Review; Systematic Review]. 2015 2015-01-01;23 Suppl 1:S8-17.

56. Chen J, Li J, Li R, Wang H, Yang J, Xu J, et al. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials. PAIN MED. [Journal Article; Meta-Analysis]. 2017 2017-02-01;18(2):374–85.
Structure of network formed by interventions. The lines between treatment nodes indicate the direct comparisons made within randomised controlled trials. Numbers (n/n) near the line indicate ‘number of trials/number of participants’ of the related comparisons. (A) the network plot of main network metanalysis. (B) the network plot of subgroup analysis comparing different selective COX-2 inhibitor and traditional NSAIDs.
Figure 2

(A) The forest plots of pain relief and function improvement for main network meta-analysis. (B) The forest plots of pain relief and function improvement for subgroup analysis comparing different selective COX-2 inhibitor and traditional NSAIDs (SMD, standardised mean difference).

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Onlineonlydocument.docx
- PRISMA2009checklist.doc